spot_img

Here’s Why Big Pharma Spends More On Ads Pushing Lower Benefit Drugs, Study Suggests

Share This Post

Big pharma spends more money on advertising for drugs that have lower health benefits for patients, according to a study published in JAMA on Tuesday, shedding new light on the almost uniquely American practice amid fierce debate over whether direct-to-consumer prescription drug ads should be banned.

The proportion of advertising spending allocated to direct-to-consumer ads was an average of 14.3 percentage points higher for drugs with a low added benefit compared to those with a high added benefit, according to the peer-reviewed analysis of the 150 best-selling branded prescription drugs in 2020.

Read More

spot_img

Related Posts

Where Big Pharma’s campaign cash is flowing in this election

Big Pharma CEOs are hedging all bets by supporting...

AMERICANS FOR PHARMA REFORM LAUNCHES RADIO AD IN MADISON

Ad highlights the hypocrisy of Senator Tammy Baldwin’s position...

Big Pharma Is a Big Menace to Global Health

Pharmaceutical companies claim their profits are necessary for vital...

Exposing Big Pharma’s Greed

Big Pharma has been playing a costly game, manipulating...

Meddling in Moderna Patent Case Undermines Pandemic Preparedness

No one ever accused politicians of consistency. For instance,...
- Advertisement -spot_img